<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1489" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1489/" /><meta name="ncbi_pagename" content="X-Linked Dystonia-Parkinsonism - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>X-Linked Dystonia-Parkinsonism - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="X-Linked Dystonia-Parkinsonism" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/02/15" /><meta name="citation_author" content="Virgilio Gerald H Evidente" /><meta name="citation_pmid" content="20301662" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1489/" /><meta name="citation_keywords" content="DYT3" /><meta name="citation_keywords" content="DYT-TAF1" /><meta name="citation_keywords" content="Lubag" /><meta name="citation_keywords" content="DYT3" /><meta name="citation_keywords" content="Lubag" /><meta name="citation_keywords" content="DYT-TAF1" /><meta name="citation_keywords" content="Transcription initiation factor TFIID subunit 1" /><meta name="citation_keywords" content="TAF1" /><meta name="citation_keywords" content="X-Linked Dystonia-Parkinsonism" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="X-Linked Dystonia-Parkinsonism" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Virgilio Gerald H Evidente" /><meta name="DC.Date" content="2018/02/15" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1489/" /><meta name="description" content="Individuals with X-linked dystonia-parkinsonism (XDP) have dystonia of varying severity and parkinsonism. XDP afflicts primarily Filipino men and, rarely, women. The mean age of onset in men is 39 years; the clinical course is highly variable with parkinsonism as the initial presenting sign, overshadowed by dystonia as the disease progresses. Features of parkinsonism include resting tremor, bradykinesia, rigidity, postural instability, and severe shuffling gait. The dystonia develops focally, most commonly in the jaw, neck, trunk, and eyes, and less commonly in the limbs, tongue, pharynx, and larynx, the most characteristic being jaw dystonia often progressing to neck dystonia. Individuals with pure parkinsonism have non-disabling symptoms that are only slowly progressive; those who develop a combination of parkinsonism and dystonia can develop multifocal or generalized symptoms within a few years and die prematurely from pneumonia or intercurrent infections. Female carriers are mostly asymptomatic, though a small minority may manifest dystonia, parkinsonism, or chorea." /><meta name="og:title" content="X-Linked Dystonia-Parkinsonism" /><meta name="og:type" content="book" /><meta name="og:description" content="Individuals with X-linked dystonia-parkinsonism (XDP) have dystonia of varying severity and parkinsonism. XDP afflicts primarily Filipino men and, rarely, women. The mean age of onset in men is 39 years; the clinical course is highly variable with parkinsonism as the initial presenting sign, overshadowed by dystonia as the disease progresses. Features of parkinsonism include resting tremor, bradykinesia, rigidity, postural instability, and severe shuffling gait. The dystonia develops focally, most commonly in the jaw, neck, trunk, and eyes, and less commonly in the limbs, tongue, pharynx, and larynx, the most characteristic being jaw dystonia often progressing to neck dystonia. Individuals with pure parkinsonism have non-disabling symptoms that are only slowly progressive; those who develop a combination of parkinsonism and dystonia can develop multifocal or generalized symptoms within a few years and die prematurely from pneumonia or intercurrent infections. Female carriers are mostly asymptomatic, though a small minority may manifest dystonia, parkinsonism, or chorea." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1489/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/xdp/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1489/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A08F6E04125D10000000001A600AB.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1489_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1489_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/csnb/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/xlhi/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1489_"><span class="title" itemprop="name">X-Linked Dystonia-Parkinsonism</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: DYT3, DYT-TAF1, Lubag</div><p class="contrib-group"><span itemprop="author">Virgilio Gerald H Evidente</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1489_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1489_ai__"><div class="contrib half_rhythm"><span itemprop="author">Virgilio Gerald H Evidente</span>, MD<div class="affiliation small">Director, Movement Disorders Center of Arizona<br />Scottsdale, Arizona<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="su.sredrosidtnemevom@etnedivev" class="oemail">su.sredrosidtnemevom@etnedivev</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">December 13, 2005</span>; Last Update: <span itemprop="dateModified">February 15, 2018</span>.</p><p><em>Estimated reading time: 30 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="xdp.Summary" itemprop="description"><h2 id="_xdp_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Individuals with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> dystonia-parkinsonism (XDP) have dystonia of varying severity and parkinsonism. XDP afflicts primarily Filipino men and, rarely, women. The mean age of onset in men is 39 years; the clinical course is highly variable with parkinsonism as the initial presenting sign, overshadowed by dystonia as the disease progresses. Features of parkinsonism include resting tremor, bradykinesia, rigidity, postural instability, and severe shuffling gait. The dystonia develops focally, most commonly in the jaw, neck, trunk, and eyes, and less commonly in the limbs, tongue, pharynx, and larynx, the most characteristic being jaw dystonia often progressing to neck dystonia. Individuals with pure parkinsonism have non-disabling symptoms that are only slowly progressive; those who develop a combination of parkinsonism and dystonia can develop multifocal or generalized symptoms within a few years and die prematurely from pneumonia or intercurrent infections. Female carriers are mostly asymptomatic, though a small minority may manifest dystonia, parkinsonism, or chorea.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of XDP is suspected in a male with typical clinical findings, family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> inheritance, and maternal ancestral roots from the Panay Islands in the Philippines. Molecular genetic testing for variants that tag a disease-associated haplotype of the multilocus transcript system termed <i>TAF/DYT3</i> is required to confirm the diagnosis in those with no known family history of XDP, very early symptoms, and/or a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of pure parkinsonism, pure tremor, or chorea without dystonia. Olfactory testing indicates olfactory dysfunction early in the disease and may be used to support the diagnosis when <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is not available.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Pharmacologic agents are used to treat dystonia or parkinsonism or both. Anticholinergic agents, benzodiazepines, and sometimes neuroleptics are used in the early stages of dystonia; zolpidem and tetrabenazine are used after dystonia becomes multifocal or generalized. Botulinum toxin injections improve focal dystonia but may worsen swallowing in individuals with preexisting dysphagia. Parkinsonism is treated with levodopa and dopamine agonists to control tremor. Bilateral pallidal deep brain stimulation may be used to treat advanced disease and medically refractory dystonia, although it may have less effect on parkinsonism.</p><p><i>Prevention of secondary complications:</i> Swallowing evaluation to guide diet modification and swallowing techniques to minimize risk of aspiration. Physical therapy, coupled with maximal medical and surgical therapy, may help delay immobility and its complications.</p><p><i>Surveillance:</i> Annual clinical evaluations in males with the disease-related haplotype who are not yet symptomatic, biannual evaluation for symptomatic males to monitor medications, and periodic swallowing evaluation, especially in those with subjective dysphagia.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>XDP is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. Approximately 94% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have a known family history of the condition. <i>De novo</i> occurrence of the disease-related haplotype associated with the disorder has not been observed to date. Males with XDP pass the <i>TAF1/DYT3</i> disease-associated haplotype to all of their daughters and none of their sons. Women who are carriers have a 50% chance of transmitting the <i>TAF1/DYT3</i> disease-associated haplotype in each pregnancy: males who inherit the <i>TAF1/DYT3</i> disease-associated haplotype will be affected; females who inherit the <i>TAF1/DYT3</i> disease-associated haplotype are mostly asymptomatic, although a small percentage may manifest symptoms. Carrier evaluation of at-risk female relatives is possible if the <i>TAF1/DYT3</i> disease-associated haplotype has been identified in the family. Once the <i>TAF1/DYT3</i> disease-associated haplotype has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for XDP are possible. Caution should be exercised in interpreting the results of prenatal testing as the c.94C&#x0003e;T (p.Arg32Cys) variant that marks the disease haplotype has not been proven to be the molecular cause of XDP.</p></div></div><div id="xdp.Diagnosis"><h2 id="_xdp_Diagnosis_">Diagnosis</h2><div id="xdp.Clinical_Diagnosis"><h3>Clinical Diagnosis</h3><p>The diagnosis of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> dystonia-parkinsonism (XDP) <b>should be suspected</b> in an individual with the following clinical findings, neuroimaging results, and neurophysiologic test results.</p><p><b>Clinical findings</b></p><ul><li class="half_rhythm"><div>Dystonia of varying severity, ranging from focal to generalized typically starting in early adulthood</div></li><li class="half_rhythm"><div>Parkinsonism</div></li><li class="half_rhythm"><div>Family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> inheritance</div></li><li class="half_rhythm"><div>Maternal ancestral roots from the Panay Islands in the Philippines where XDP originated as a genetic <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a>. All known <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals to date are of Filipino descent.</div></li></ul><p><b>Neuroimaging.</b> CT and brain MRI in 20 individuals with symptomatic XDP did not reveal significant striatal or brain stem atrophy [Evidente, personal observation]. Generalized cerebral atrophy (usually mild) may be seen in some individuals. Caudate atrophy on brain imaging can be seen in individuals with more advanced disease similar to that seen in <a href="/books/n/gene/huntington/">Huntington disease</a>, though this is not a consistent finding.</p><p><b>Neurophysiologic testing</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Olfactory.</b> The degree of olfactory impairment in XDP can be as severe as that seen in Parkinson disease. <a class="bk_pop" href="#xdp.REF.evidente.2004a.407">Evidente et al [2004a]</a> administered a culturally corrected University of Pennsylvania Smell Identification Test (ccUPSIT) consisting of 25 odor items to 20 symptomatic males with XDP and 20 controls. The mean ccUPSIT score of individuals with XDP (18&#x000b1;3.19) was significantly lower (p=0.003) than that of controls (20.5&#x000b1;3.02). The olfactory scores did not correlate with <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, severity of dystonia, or duration of disease. Nine of 20 individuals with XDP (45%) had ccUPSIT scores below the mean, with the lowest score being 11, suggesting that olfactory dysfunction may occur in individuals with XDP even early in the disease.</div><div class="half_rhythm">As genetic testing is often not available in the endemic rural areas in the Philippines, olfactory testing may support the diagnosis in symptomatic (and possibly presymptomatic) individuals with XDP, though this possibility needs to be studied further.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Other.</b> Nerve conduction studies, somatosensory evoked potential studies, electroencephalography, blink reflex studies, and brain stem evoked potential studies in ten symptomatic males with XDP with dystonia and parkinsonism have revealed no abnormalities [Evidente, personal observation].</div></li></ul></div><div id="xdp.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p><b>Male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of XDP <b>is established</b> in a male proband with typical clinical and neuroimaging findings. In those with no known family history of XDP, very early symptoms, and/or a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of pure parkinsonism, pure tremor, or chorea without dystonia, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is required to confirm the diagnosis. A single haplotype of the multilocus transcript system termed <i>TAF1/DYT3</i> is the only <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> associated with XDP. The molecular cause of XDP has not been determined; therefore, variants on the <i>TAF1/DYT3</i> disease-associated haplotype are used as a marker for XDP (see <a class="figpopup" href="/books/NBK1489/table/xdp.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figxdpTmoleculargenetictestingusedin" rid-ob="figobxdpTmoleculargenetictestingusedin">Table 1</a>).</p><p><b>Female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of XDP <b>is usually established</b> in a symptomatic female proband with a family history of XDP who presents with either chorea, pure parkinsonism, focal dystonia, or (rarely) generalized dystonia; it is confirmed by identification of a <i>TAF1/DYT3</i> disease-associated haplotype (see <b>Male proband</b> and <a class="figpopup" href="/books/NBK1489/table/xdp.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figxdpTmoleculargenetictestingusedin" rid-ob="figobxdpTmoleculargenetictestingusedin">Table 1</a>).</p><p><b>Molecular genetic testing.</b> Approaches can include <b>targeted analysis</b> for a <i>TAF1/DYT3</i> disease-associated haplotype and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Targeted analysis</b> for the XDP-disease-specific sequence variant <a class="figpopup" href="/books/NBK1489/table/xdp.T.selected_variants_within_the_xdp_c/?report=objectonly" target="object" rid-figpopup="figxdpTselectedvariantswithinthexdpc" rid-ob="figobxdpTselectedvariantswithinthexdpc">c.94C&#x0003e;T</a> (<a class="figpopup" href="/books/NBK1489/table/xdp.T.selected_variants_within_the_xdp_c/?report=objectonly" target="object" rid-figpopup="figxdpTselectedvariantswithinthexdpc" rid-ob="figobxdpTselectedvariantswithinthexdpc">p.Arg32Cys</a>) is consistent with the diagnosis in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; however, this is an indirect test. See Note (1).</div><div class="half_rhythm">Note: (1) Although detection of c.94C&#x0003e;T (p.Arg32Cys) in a symptomatic individual is considered diagnostic, this is an indirect finding. Variants at this <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> not previously associated with XDP cannot be interpreted as disease associated (see <a href="#xdp.Genetically_Related_Allelic_Disorder">Genetically Related Disorders</a>). (2) This variant has only been associated with XDP in individuals of Filipino ancestry. (3) Recent data suggest that a haplotype-tagging SVA (<i>s</i>hort interspersed nuclear element, <i>v</i>ariable number of tandem repeats, and <i>A</i>lu composite) retrotransposon <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> in <i>TAF1</i>, which contains an unstable repeat expansion, may be the causative variant. Note that due to the context of the sequence, testing for this SVA and repeat expansion poses a technical challenge for molecular testing [<a class="bk_pop" href="#xdp.REF.makino.2007.393">Makino et al 2007</a>, <a class="bk_pop" href="#xdp.REF.bragg.2017.e11020">Bragg et al 2017</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes XDP-specific sequence variants and other genes of interest (see <a href="#xdp.Differential_Diagnosis">Differential Diagnosis</a>) may be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="xdp.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in X-Linked Dystonia-Parkinsonism</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1489/table/xdp.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xdp.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_xdp.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene/ Locus&#x000a0;<sup>1</sup></th><th id="hd_h_xdp.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_xdp.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_xdp.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TAF1/DYT3</i></td><td headers="hd_h_xdp.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for the XDP-specific sequence variant c.94C&#x0003e;T (p.Arg32Cys)&#x000a0;<sup>3</sup></td><td headers="hd_h_xdp.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100% in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals of Filipino descent&#x000a0;<sup>4</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="xdp.TF.1.1"><p class="no_margin">See <a href="/books/NBK1489/#xdp.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="xdp.TF.1.2"><p class="no_margin">See <a href="#xdp.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="xdp.TF.1.3"><p class="no_margin">A variety of molecular methods may be used to detect a specific variant. If <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> is performed, variants other than the c.94C&#x0003e;T (p.Arg32Cys) may be detected. For issues to consider in interpretation of sequence analysis results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="xdp.TF.1.4"><p class="no_margin">The common c.94C&#x0003e;T (p.Arg32Cys) variant (historically known as disease-specific single-nucleotide change 3 (DSC3) is the only DSC embedded in a predicted <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a>; see <a class="figpopup" href="/books/NBK1489/table/xdp.T.selected_variants_within_the_xdp_c/?report=objectonly" target="object" rid-figpopup="figxdpTselectedvariantswithinthexdpc" rid-ob="figobxdpTselectedvariantswithinthexdpc">Table 2</a>). Four additional DSCs and a 48-bp <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> that were unique to XDP were identified [<a class="bk_pop" href="#xdp.REF.nolte.2003.10347">Nolte et al 2003</a>]. In addition, an SVA retrotransposon <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> in <i>TAF1</i> has also been identified on the XDP haplotype [<a class="bk_pop" href="#xdp.REF.makino.2007.393">Makino et al 2007</a>]. The molecular cause of XDP is unknown. See <a href="#xdp.Molecular_Genetics">Molecular Genetics</a> for details on the multilocus transcript.</p></div></dd></dl></div></div></div></div></div><div id="xdp.Clinical_Characteristics"><h2 id="_xdp_Clinical_Characteristics_">Clinical Characteristics</h2><div id="xdp.Clinical_Description"><h3>Clinical Description</h3><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> dystonia-parkinsonism (XDP) or <i>lubag</i> afflicts primarily adult Filipino men and, rarely, women. The male-to-female ratio is 99:1. The mean age of onset in men is 39 years, with a range of 12 to 64 years. The mean age of onset in women is 52 years, with a range of 26 to 75 years [<a class="bk_pop" href="#xdp.REF.evidente.2004b.1956">Evidente et al 2004b</a>]. The time from onset of dystonia to generalization ranges from one to 23 years, with a mean of 3.8 years.</p><p>The clinical course in men with XDP is highly variable. Although the presenting finding was traditionally thought to be dystonia in most cases [<a class="bk_pop" href="#xdp.REF.lee.2002.29">Lee et al 2002</a>], a longitudinal follow up of asymptomatic or early symptomatic individuals with genetically confirmed XDP revealed that the initial presenting sign is almost universally parkinsonism [<a class="bk_pop" href="#xdp.REF.evidente.2002c.200">Evidente et al 2002c</a>]. In particular, abnormality of rapid alternating limb movements (which can be asymmetric) can often be appreciated on neurologic examination in early symptomatic (or soon to be symptomatic) individuals.</p><p><b>Parkinsonism.</b> Individuals with XDP may present predominantly with one or more of the cardinal features of Parkinson disease, including resting tremor, bradykinesia, rigidity, and postural instability. Shuffling gait, in the absence of lower-limb dystonia, can be severe enough to cause recurrent falls and significant impairment of walking.</p><p>Some individuals may have pure parkinsonism and no dystonia for many years [<a class="bk_pop" href="#xdp.REF.evidente.2002c.200">Evidente et al 2002c</a>]. In some of these individuals, the dystonia develops very late in the course and is usually focal or segmental. When the dystonia becomes advanced (i.e., multifocal or generalized in distribution), the parkinsonism remains, although it is overshadowed by the dystonia.</p><p>Some individuals with XDP (both male and female) may have all the cardinal features of parkinsonism, asymmetric findings, and levodopa responsiveness. These individuals may initially be misdiagnosed as having Parkinson disease [<a class="bk_pop" href="#xdp.REF.evidente.2002c.200">Evidente et al 2002c</a>, <a class="bk_pop" href="#xdp.REF.domingo.2014.1177">Domingo et al 2014</a>].</p><p><b>Dystonia.</b> The dystonia develops focally, most commonly in the jaw, neck, trunk, and eyes, and less commonly in the limbs, tongue, pharynx, and larynx.</p><p>The most characteristic dystonia seen in males with XDP is jaw dystonia, more commonly presenting as more difficulty with jaw opening than jaw closing. Jaw dystonia often progresses to neck dystonia, with retrocollis being more common than torticollis. Retrocollis can be so severe that the neck is extended more than 90 degrees, and the trunk is hyperextended. Cervical dystonia may be accompanied by a dystonic head tremor. Extension dystonia of the trunk is far more common than flexion or lateral dystonia of the trunk.</p><p>Blepharospasm is only rarely the initial symptom of XDP. It tends to be more common as the disease progresses. It can coexist with mid- or lower-facial dystonia.</p><p>Limb dystonia, rarely an initial presenting finding, is more commonly seen as disease advances. It affects the upper limbs as often as the lower limbs and is usually bilateral, although severity can be greater on one side of the body than the other. Unlike DYT1 torsion dystonia, XDP only rarely presents with dystonia of the foot.</p><p>Tongue dystonia may also be seen, manifesting as either involuntary tongue protrusion or limitation in tongue protrusion. Pharyngeal dystonia, manifesting as difficulty swallowing, usually affects those with orolingual dystonia. Pharyngeal dystonia often leads to significant weight loss, aspiration pneumonia, and early death.</p><p>Laryngeal dystonia leading to stridor (a rare finding) can also lead to sudden death. Individuals with orolingual, pharyngeal, or laryngeal dystonia may present with respiratory sounds [<a class="bk_pop" href="#xdp.REF.evidente.2002a.1271">Evidente et al 2002a</a>]. Such vocalizations can be observed during both inspiration and expiration.</p><p>Sensory tricks (improvement in dystonia by touching certain areas) have been observed in individuals with XDP with dystonia, particularly those with cervical dystonia.</p><p><b>Other neurologic findings.</b> Traditionally, XDP was thought to be a combination of dystonia and parkinsonism only [<a class="bk_pop" href="#xdp.REF.evidente.2002a.1271">Evidente et al 2002a</a>]; however, with genotypic correlation, other neurologic findings including pure tremor, chorea, athetosis, and myoclonus have been recognized:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Resting tremor or action tremor</b> can be seen in either the early or later stages of disease. In some individuals, an asymmetric resting tremor of a limb with an oscillation of 3-6 Hz (similar to that seen in Parkinson disease) can be observed. Some individuals may also have a coarse, relatively symmetric upper-limb tremor or head tremor similar to that in individuals with essential tremor. The tremor can involve not only the limbs and head, but also the trunk, craniofacial region (lips, jaw, or facial muscles), and voice. Distal limb tremor can sometimes be of slow frequency (1-3 Hz), reminiscent of myorhythmia [<a class="bk_pop" href="#xdp.REF.evidente.2002a.1271">Evidente et al 2002a</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Chorea</b> usually occurs in the distal upper limbs in the early stages and is combined with subtle dystonia, thus resulting in athetotic movements. Chorea can also be seen with the generalized dystonic movements.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Action myoclonus</b> can be present in the limbs or even in the craniofacial region. Myoclonus is characterized by a combination of rapid, brief, lightning-like muscle contractions and is often mistaken for tremor.</div><div class="half_rhythm">Electrophysiologic studies show muscle bursts &#x02264;50-100 milliseconds in duration. Back-averaging may show a jerk-locked pre-movement surface-positive cortical electroencephalographic potential in the contralateral sensorimotor area, supporting the cortical origin of the myoclonus.</div></li></ul><p><b>General cognition</b> often remains intact although there may be problems with frontal executive functions [<a class="bk_pop" href="#xdp.REF.domingo.2011.s264">Domingo et al 2011</a>].</p><p><b>Depression</b> is also a common feature, most likely related to the profound disability and loss of employment that XDP causes, especially in more advanced cases [<a class="bk_pop" href="#xdp.REF.morigaki.2013.844">Morigaki et al 2013</a>]. Impulse control disorder in the form of pathological gambling has been described in XDP [<a class="bk_pop" href="#xdp.REF.gillian.2013.299">Gillian 2013</a>].</p><p><b>Disease progression.</b> Those with pure parkinsonism with little or no dystonia have the best prognosis; they have non-disabling symptoms that are slowly progressive or non-progressive.</p><p>Those who develop a combination of parkinsonism and orobuccolingual dystonia and cervical dystonia in the first year or two of the disease have the worst prognosis. Such individuals develop multifocal or generalized symptoms from the second to fifth year after onset, rapidly become bedridden, and die prematurely from aspiration pneumonia, laryngeal stridor, and/or intercurrent infections resulting from immobility.</p><p><b>Phenotype in women.</b> Female XDP carriers are mostly asymptomatic, although a small percentage may manifest symptoms. Compared to men, women with XDP often do not present with dystonia, or if they do, the dystonia is usually focal, non-progressive, and non-disabling [<a class="bk_pop" href="#xdp.REF.evidente.2004b.1956">Evidente et al 2004b</a>]. The dystonia can subtly manifest in the neck or limbs. However, there have been rare cases of women with XDP who have generalized dystonia similar to that seen in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> men [<a class="bk_pop" href="#xdp.REF.lee.2011.3">Lee et al 2011</a>].</p><p>Other manifestations in women include chorea (which can be in a hemi-distribution), focal tremor (usually limb), or parkinsonism. The parkinsonism is usually mild, non-progressive, and non-disabling. Rarely, levodopa-responsive parkinsonism very similar to Parkinson disease can be observed.</p><p><b>Neuroimaging studies</b> have revealed the following:</p><ul><li class="half_rhythm"><div>Normal findings on CT and brain MRI in the majority of patients, although generalized cerebral atrophy (usually mild) may be seen in some individuals and caudate atrophy in more advanced disease [Evidente, personal observation]</div></li><li class="half_rhythm"><div>Evidence for strong involvement of the white matter and putamen based on diffusion-weighted imaging [<a class="bk_pop" href="#xdp.REF.br_ggemann.2016.91">Br&#x000fc;ggemann et al 2016</a>]</div></li><li class="half_rhythm"><div>Evidence of both postsynaptic [<a class="bk_pop" href="#xdp.REF.eidelberg.1993.185">Eidelberg et al 1993</a>] and presynaptic nigrostriatal involvement [<a class="bk_pop" href="#xdp.REF.waters.1993.1555">Waters et al 1993</a>] on [<sup>18</sup>F] fluorodopa PET scan studies</div></li><li class="half_rhythm"><div>Putaminal abnormalities on flurodeoxyglucose (FDG) PET scan in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> men with early or mild symptomatic <i>lubag</i> despite normal brain CT or MRIs [<a class="bk_pop" href="#xdp.REF.evidente.2002d.626">Evidente et al 2002d</a>]</div></li><li class="half_rhythm"><div>Results on presynaptic single-photon emission computed tomography (SPECT) studies using either [<sup>123</sup>I]-&#x003b2;-carbomethoxy-iodophenyl-nortropane (CIT) or ioflupane I-123 dopamine transporter (DaT scan) which can be similar to those seen in individuals with <a href="/books/n/gene/parkinson-overview/">Parkinson disease</a>, with the putamina involved more severely than the caudate, and one side more <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> than the other [<a class="bk_pop" href="#xdp.REF.tackenberg.2007.900">Tackenberg et al 2007</a>; Evidente, personal observation]. DAT scan abnormalities are noted even in early XDP with pure parkinsonism, or with only mild dystonia.</div></li><li class="half_rhythm"><div>Functional decline of postsynaptic dopaminergic transmission related to disease duration and ongoing degeneration function on [<sup>123</sup>I] (IBZM)-SPECT studies [<a class="bk_pop" href="#xdp.REF.br_ggemann.2017.680">Br&#x000fc;ggemann et al 2017</a>].</div></li><li class="half_rhythm"><div>Hyperechogenicity of the substantia nigra in 79% and of the lenticular nuclei in 81% of individuals with XDP on transcranial brain sonography studies [<a class="bk_pop" href="#xdp.REF.walter.2017.43">Walter et al 2017</a>]. Abnormal substantia nigra hyperechogenicity was more frequent in individuals with prominent parkinsonism (100%) compared to those without (68%). Thus, substantia nigra hyperechogenicity may be regarded as a preclinical risk marker of parkinsonism-predominant XDP.</div></li></ul><p>Thus, it appears that by functional imaging, individuals with XDP may have one of the following:</p><ul><li class="half_rhythm"><div><b>Postsynaptic striatal involvement.</b> Affected individuals may represent the majority of XDP, with pure dystonia or combined dystonia-parkinsonism from the early stages; this group does not respond to levodopa.</div></li><li class="half_rhythm"><div><b>Presynaptic nigrostriatal involvement.</b> Affected individuals may represent those few who have pure parkinsonism for a considerable number of years, with dystonia setting in late in the course; this group appears to be more responsive to levodopa.</div></li></ul><p><b>Neuropathology.</b> Little information is available on the neuropathology of XDP.</p><p>The earliest neuropathology report on XDP, from one Filipino male with dystonia-parkinsonism, showed neuronal loss and a multifocal mosaic pattern of astrocytosis in the caudate and lateral putamen [<a class="bk_pop" href="#xdp.REF.waters.1993.1555">Waters et al 1993</a>]. This information has been updated by <a class="bk_pop" href="#xdp.REF.pasco.2011.12">Pasco et al [2011]</a>, who report that "[i]n the neostriatum, the dystonic phase of XDP shows the involvement of striosomes and matrix sparing, while the later, i.e., parkinsonian phase, shows matrix involvement as well. In the dystonic phase, the loss of striosomal inhibitory projections lead to disinhibition of nigral dopaminergic neurons, perhaps resulting in a hyperkinetic state; while in the parkinsonian phase, severe and critical reduction of matrix-based projection may result in extranigral parkinsonism."</p><p>Neuropathologic examination on an individual with severe generalized dystonia and parkinsonism confirmed the mosaic pattern of striatal gliosis as reported earlier, but also noted that the gliotic patches showed gradients that were dorsal to ventral, rostral to caudal, and medial to lateral [<a class="bk_pop" href="#xdp.REF.evidente.2002b.294">Evidente et al 2002b</a>]. The caudate was more <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> than the putamen, and the accumbens was largely spared. The head of the caudate was more affected than the tail. The patchy areas of striatal gliosis were not associated with microglial activation. The more marked involvement of caudate and putamen than of the ventral, limbic striatum (i.e., nucleus accumbens) suggests that striatal synaptic input from the limbic lobe is less affected than the synaptic input from the sensorimotor and association cortices. With synaptic immunostaining, it was noted that the patchy areas of gliosis corresponded to the areas of poor synaptophysin staining, suggesting that the basis for the patchy gliosis is synaptic loss rather than neuronal loss. The synaptic loss and gliosis were also observed in the globus pallidus interna and externa. Some focal gliosis was also noted in the substantia nigra pars reticularis, but not in the pars compacta.</p><p>Postmortem analyses of the basal ganglia based on striatal compartments (i.e., the striosomes and the matrix compartment) showed that in the neostriatum of individuals with XDP, the striosomes are severely depleted while the matrix component is relatively spared [<a class="bk_pop" href="#xdp.REF.goto.2005.7">Goto et al 2005</a>]. Thus, the disproportionate involvement of the neostriatum compartments and their efferent projections may be responsible for dystonia in XDP and possibly in other neurodegenerative disorders.</p><p>Neuropathologic studies have shown a neostriatal defect of the neuropeptide Y system in individuals with XDP, suggesting that the neuropeptide Y system may play a role in the progressive loss of striatal neurons [<a class="bk_pop" href="#xdp.REF.goto.2013.1555">Goto et al 2013</a>].</p></div><div id="xdp.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>All symptomatic individuals have the same disease-associated <i>TAF1/DYT3</i> haplotype regardless of <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#xdp.REF.nolte.2003.10347">Nolte et al 2003</a>], which comprises a spectrum including pure parkinsonism, focal dystonia, segmental dystonia, multifocal dystonia, and generalized dystonia in symptomatic men and chorea, pure parkinsonism, and focal or multifocal dystonia in symptomatic women.</p><p>Recently, <a class="bk_pop" href="#xdp.REF.bragg.2017.e11020">Bragg et al [2017]</a> have further analyzed the sequence of the SVA in <i>TAF1</i> and detected polymorphic variation in the length of a hexanucleotide repeat <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, (CCCTCT)n, which varies from 35 to 52 repeats. The length of the repeat correlates inversely with age at disease onset [<a class="bk_pop" href="#xdp.REF.bragg.2017.e11020">Bragg et al 2017</a>].</p></div><div id="xdp.Anticipation"><h3>Anticipation</h3><p>Anticipation is not observed in XDP.</p></div><div id="xdp.Nomenclature"><h3>Nomenclature</h3><p>XDP was first described by <a class="bk_pop" href="#xdp.REF.lee.1976.137">Lee et al [1976]</a> as "dystonia musculorum deformans."</p><p>In the local Filipino dialect, <i>lubag</i> describes intermittent twisting or posturing. Other terms used include wa-eg (sustained postures) and <i>sud-sud</i> (shuffling gait), which are commonly seen in persons with XDP.</p></div><div id="xdp.Prevalence"><h3>Prevalence</h3><p>The first epidemiologic study was by <a class="bk_pop" href="#xdp.REF.lee.1976.137">Lee et al [1976]</a>. More than 500 cases of XDP have been described in the literature. XDP is believed to have originated ancestrally in the Philippines, particularly in the Panay Islands through a <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> some 50 meiotic generations (~1,000 years) ago. The prevalence rate is 5.24:100,000 in the Panay Islands, with the highest rate of 18.9:100,000 in the province of Capiz, where it is endemic [<a class="bk_pop" href="#xdp.REF.lee.2002.29">Lee et al 2002</a>].</p><p>The prevalence in the general population in the Philippines is estimated at 0.34:100,000.</p><p>Although maternal ancestry can be traced to the Panay Islands in most cases, some individuals have no such traceable ancestry.</p></div></div><div id="xdp.Genetically_Related_Allelic_Disorder"><h2 id="_xdp_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>Hemizygous, usually <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>, pathogenic variants in <i>TAF1</i> (other than the c.94C&#x0003e;T (p.Arg32Cys) variant) have been associated with a <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> neurodevelopmental disorder characterized by global developmental delay, intellectual disability, and <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> facial features (OMIM <a href="http://omim.org/entry/300966" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">300966</a>).</p></div><div id="xdp.Differential_Diagnosis"><h2 id="_xdp_Differential_Diagnosis_">Differential Diagnosis</h2><p>See <a href="/books/n/gene/dystonia-ov/">Dystonia Overview</a>.</p><p>Individuals with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> dystonia-parkinsonism (XDP) with tremor can be misdiagnosed as having <a href="/books/n/gene/parkinson-overview/">Parkinson disease</a> or essential tremor, especially in the early stages in which dystonia may be absent or subtle. Individuals with XDP with all the cardinal features of parkinsonism, asymmetric findings, and levodopa responsiveness are often diagnosed as having Parkinson disease or Parkinson-plus syndrome.</p></div><div id="xdp.Management"><h2 id="_xdp_Management_">Management</h2><div id="xdp.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> dystonia-parkinsonism (XDP) syndrome, the following evaluations are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>Neurologic examination</div></li><li class="half_rhythm"><div>Assessment of speech</div></li><li class="half_rhythm"><div>Assessment of swallowing</div></li><li class="half_rhythm"><div>Nutritional assessment</div></li><li class="half_rhythm"><div>Surface electromyography study</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="xdp.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div id="xdp.Pharmacologic_Treatment_of_Dystonia"><h4>Pharmacologic Treatment of Dystonia</h4><p><b>Anticholinergic agents and benzodiazepines.</b> In the early stages of the disease when dystonia is focal or segmental in distribution, individuals may respond significantly to anti-dystonia medications, particularly to anticholinergic agents and benzodiazepines.</p><ul><li class="half_rhythm"><div>The two most commonly prescribed anticholinergic drugs are trihexyphenidyl (Artane&#x02122;) and biperiden (Akineton&#x02122;). Trihexyphenidyl appears to have a more consistent and beneficial effect than biperiden, especially in the moderate-to-advanced stages.</div></li><li class="half_rhythm"><div>The benzodiazepine associated with the best response is clonazepam.</div></li><li class="half_rhythm"><div>Even greater improvement in dystonia is noted when anticholinergic drugs are combined with clonazepam.</div></li></ul><p><b>Zolpidem.</b> Once the dystonia is multifocal or generalized in distribution, even polypharmacy offers only partial relief of the dystonic symptoms. In such states, zolpidem has been observed to be potentially effective [<a class="bk_pop" href="#xdp.REF.evidente.2002.662">Evidente 2002</a>].</p><p>Zolpidem is particularly useful in individuals with a predominantly phasic type of generalized dystonic movements and no contractures. In such cases dramatic improvement can occur: some individuals experience nearly 100% improvement of dystonia for a few hours.</p><ul><li class="half_rhythm"><div>The clinical effect of zolpidem may last six to eight hours per 10-mg dose in the first few weeks. Subsequently, the effect becomes progressively shorter, decreasing to two to three hours.</div></li><li class="half_rhythm"><div>Zolpidem was previously reported to have modest effects on parkinsonism in some individuals with progressive supranuclear palsy (PSP) [<a class="bk_pop" href="#xdp.REF.daniele.1999.543">Daniele et al 1999</a>] and Parkinson disease [<a class="bk_pop" href="#xdp.REF.daniele.1997.1222">Daniele et al 1997</a>]; its effect on dystonia in individuals with XDP is more robust than its effect on parkinsonism.</div></li><li class="half_rhythm"><div>Individuals with XDP who take frequent doses of zolpidem either overcome its soporific effects rapidly or develop tolerable daytime sleepiness.</div></li></ul><p><b>Neuroleptics,</b> particularly those with strong dopamine D<sub>2</sub> antagonistic properties, are often prescribed because they are relatively cheap and widely available.</p><ul><li class="half_rhythm"><div>Haloperidol is often used by primary care physicians who see individuals with XDP <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> in the Panay Islands. Although haloperidol may be effective initially for mild-to-moderate dystonia, its effect in more advanced dystonia remains dubious, as it is unclear if the progression of the dystonia is caused by the disease alone or partially caused by the extrapyramidal side effects (EPS) of haloperidol.</div></li><li class="half_rhythm"><div>Risperidone appears less effective than haloperidol in controlling dystonia. At doses of 6 mg/day or higher, risperidone may also be associated with EPS including tardive dyskinesias and parkinsonism.</div></li><li class="half_rhythm"><div>Of the atypical neuroleptics, clozapine has the greatest potential to be effective, at least for a limited period. However, its clinical use is limited by its potential to cause aplastic anemia and the need to do frequent complete blood counts, which is impractical in the rural areas of the Panay Islands where XDP is most prevalent.</div></li></ul><p><b>Tetrabenazine</b> (a non-neuroleptic presynaptic dopamine depleter) also benefits some individuals with clinically advanced dystonia [<a class="bk_pop" href="#xdp.REF.evidente.2002a.1271">Evidente et al 2002a</a>]. Similar to zolpidem, tetrabenazine best helps individuals with phasic dystonia and no contractures.</p><p><b>Botulinum toxin injections</b> improve focal dystonia, particularly cervical dystonia, blepharospasm, tongue dystonia, and jaw dystonia. It can, however, dramatically worsen swallowing in individuals with preexisting dysphagia if injected in the cervical or tongue area. The prohibitive cost of botulinum toxin also limits its use in individuals with XDP in rural areas. <a class="bk_pop" href="#xdp.REF.rosales.2011.44">Rosales et al [2011]</a> using botulinum toxin-A injections in 109 persons with XDP found substantial improvement for oromandibular and lingual dystonias and moderate improvement for truncal-axial dystonias as well as a significant reduction in associated pain.</p><p><b>Injections of ethanol and lidocaine</b> for afferent blocking of muscle are far less costly than botulinum toxin and have been attempted in individuals with XDP with cervical dystonia. They only offer clinical benefits for one to two weeks and are associated with undesirable side effects including severe pain during injections and muscle fibrosis and contractures with repeated use.</p></div><div id="xdp.Pharmacologic_Treatment_of_Parkinson"><h4>Pharmacologic Treatment of Parkinsonism</h4><p><b>Levodopa.</b> Individuals with XDP, particularly those with pure parkinsonism, may be responsive to levodopa. Persons with parkinsonism who develop dystonia may become increasingly less responsive to levodopa as the dystonia progresses. Of note, long-term use of levodopa does not lead to development of levodopa-associated dyskinesias.</p><p><b>Dopamine agonists</b> are also effective in controlling tremor in individuals with XDP but are less effective than levodopa in controlling bradykinesia or shuffling gait. Rarely, levodopa or dopamine agonists may exacerbate the dystonia in persons with XDP.</p></div><div id="xdp.Surgical_Treatment_of_Dystonia_and_P"><h4>Surgical Treatment of Dystonia and Parkinsonism</h4><p><b>Deep brain stimulation (DBS).</b> XDP was successfully treated in one individual using DBS of the globus pallidus interna (GPi) bilaterally [<a class="bk_pop" href="#xdp.REF.evidente.2007.1790">Evidente et al 2007</a>]. The individual had parkinsonism and generalized dystonia, with severe disabling jaw-opening dystonia, drooling, dysphagia, and dysarthria (speech was unintelligible). He received only partial relief of his symptoms with a combination of levodopa, piribedil (a dopamine agonist), trihexyphenidyl, and zolpidem. His generalized dystonia and parkinsonism improved markedly within the first week after surgery, with sustained benefits at 13-year follow up. Thus, it appears that bilateral pallidal stimulation may be the best option for symptomatic improvement in individuals with XDP with advanced disease and medically refractory dystonia [<a class="bk_pop" href="#xdp.REF.wadia.2010.1012">Wadia et al 2010</a>, <a class="bk_pop" href="#xdp.REF.aguilar.2011.57">Aguilar et al 2011</a>, <a class="bk_pop" href="#xdp.REF.patel.2014.241.e1">Patel et al 2014</a>].</p><p>DBS has been done so far primarily on individuals with more advanced dystonia, either multifocal or generalized. However, a Filipino male age 45 years with only three years of relatively mild symptoms of unilateral big toe extension dystonia, mild jaw-opening dystonia, mild parkinsonism, and dysarthria underwent bilateral pallidal GPi DBS, with significant improvement of his symptoms immediately post-op [Evidente, unpublished data]. As of latest follow up 18 months after DBS, his symptoms remain well controlled with no further spread of dystonia to other parts of the body. This individual is the earliest known with XDP to have undergone DBS during the initial stages of the disease. Long-term follow up as well as identification of other cases treated early in the course of the disease may help determine if performing DBS early in the stages of XDP may have a disease-modifying effect.</p><p>Although dystonia uniformly improves in individuals with XDP undergoing bilateral pallidal DBS, the parkinsonism may be less responsive [<a class="bk_pop" href="#xdp.REF.oyama.2010.329">Oyama et al 2010</a>]. In one individual with XDP rapidly progressive dystonia was noted to have early and marked benefit with bilateral GPi DBS [<a class="bk_pop" href="#xdp.REF.martineztorres.2009.1710">Martinez-Torres et al 2009</a>]. In another individual with XDP who underwent bilateral pallidal DBS, an impulse control disorder similar to what is observed in people with Parkinson disease who have undergone DBS was described [<a class="bk_pop" href="#xdp.REF.piano.2013.1069">Piano &#x00026; Tan 2013</a>].</p></div></div><div id="xdp.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>See <a href="#xdp.Treatment_of_Manifestations">Treatment of Manifestations</a>.</p></div><div id="xdp.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>The secondary complications of significant dysphagia and immobility are usually related to progression of dystonia.</p><p>Swallowing evaluation, especially in those with subjective dysphagia, can guide diet modification and use of swallowing techniques that minimize the risk for aspiration pneumonia.</p><p>Physical therapy, coupled with maximal medical and surgical therapy, may help delay the bedridden state and its complications.</p><p>Although traditional neuroleptics may initially help focal or segmental dystonia, they may eventually exacerbate the underlying parkinsonism in individuals with XDP and also lead to tardive dystonia with chronic use. Thus, it may be difficult to determine with chronic therapy if traditional neuroleptics actually help or worsen dystonia in individuals with XDP.</p></div><div id="xdp.Surveillance"><h3>Surveillance</h3><p>Presymptomatic males known to have the disease-associated haplotype may need yearly clinical evaluations after age 30 years to identify the onset of symptoms in order to institute appropriate therapy as early as possible.</p><p>Once an individual is symptomatic, biannual follow ups are recommended in order to adjust medications to assure best management of dystonia and/or parkinsonism.</p><p>Periodic swallowing evaluation, especially in those with subjective dysphagia, is appropriate.</p></div><div id="xdp.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#xdp.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="xdp.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div><div id="xdp.Other"><h3>Other</h3><p>Other sleep medications such as zaleplon (Sonata&#x02122;) have had no beneficial effect on dystonia in individuals with XDP.</p><p>Drugs that have been used anecdotally with poor or inconsistent effects on dystonia in individuals with XDP include gabapentin, topiramate, baclofen, and tizanidine.</p><p>Brain surgeries for advanced dystonia in individuals with XDP that have failed in the past include four thalamotomies, two pallidotomies, and one cerebellar implantation [<a class="bk_pop" href="#xdp.REF.lee.2002.29">Lee et al 2002</a>].</p></div></div><div id="xdp.Genetic_Counseling"><h2 id="_xdp_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="xdp.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> dystonia-parkinsonism (XDP) is inherited in an X-linked manner.</p></div><div id="xdp.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will not have the disease nor will he be a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of the <i>TAF1/DYT3</i> disease-associated haplotype.</div></li><li class="half_rhythm"><div>In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-carrier/">obligate carrier</a>.</div></li><li class="half_rhythm"><div>Approximately 94% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have a known family history of the condition.</div></li><li class="half_rhythm"><div>When an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male is the only affected individual in the family (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case), it is likely that his mother has the <i>TAF1</i>/<i>DYT3</i> disease-associated haplotype that she inherited from a maternal female ancestor.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status of the mother:</p><ul><li class="half_rhythm"><div>Most often, the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> and the chance of transmitting the <i>TAF1/DYT3</i> disease-associated haplotype in each pregnancy is 50%. Male sibs who inherit the <i>TAF1/DYT3</i> disease-associated haplotype will eventually develop symptoms; female sibs who inherit the <i>TAF1/DYT3</i> disease-associated haplotype will be carriers and will usually not be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li><li class="half_rhythm"><div>There is no evidence to date of <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> occurrence of the disease-related haplotype associated with XDP, although it remains a possibility. In the unlikely circumstance that the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is not a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, the risk to the sibs is low, but greater than that of the general population because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Males with XDP will pass the <i>TAF1/DYT3</i> disease-associated haplotype to all of their daughters and none of their sons.</p><p><b>Other family members.</b> The <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s maternal aunts may be at risk of being carriers and of being mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, and the aunt's offspring, depending on their gender, may be at risk of being carriers and/or of being affected.</p></div><div id="xdp.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier evaluation of at-risk female relatives is possible if the <i>TAF1/DYT3</i> disease-associated haplotype has been identified in the family.</p></div><div id="xdp.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Predictive testing (i.e., testing of asymptomatic at-risk individuals)</b></p><ul><li class="half_rhythm"><div>Predictive testing for at-risk male relatives is possible once the <i>TAF1/DYT3</i> disease-associated haplotype has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member. Note: Caution should be exercised in interpreting the results of predictive testing as the <a class="figpopup" href="/books/NBK1489/table/xdp.T.selected_variants_within_the_xdp_c/?report=objectonly" target="object" rid-figpopup="figxdpTselectedvariantswithinthexdpc" rid-ob="figobxdpTselectedvariantswithinthexdpc">c.94C&#x0003e;T</a> (<a class="figpopup" href="/books/NBK1489/table/xdp.T.selected_variants_within_the_xdp_c/?report=objectonly" target="object" rid-figpopup="figxdpTselectedvariantswithinthexdpc" rid-ob="figobxdpTselectedvariantswithinthexdpc">p.Arg32Cys</a>) variant that marks the disease haplotype has not been proven to be the molecular cause of XDP.</div></li><li class="half_rhythm"><div>Potential consequences of such testing (including but not limited to socioeconomic changes and the need for long-term follow up and evaluation arrangements for individuals with a positive test result) as well as the capabilities and limitations of predictive testing should be discussed in the context of formal <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> prior to testing.</div></li></ul><p><b>Predictive testing in minors (i.e., testing of asymptomatic at-risk individuals younger than age 18 years)</b></p><ul><li class="half_rhythm"><div>For asymptomatic minors at risk for adult-onset conditions for which early treatment would have no beneficial effect on disease morbidity and mortality, predictive genetic testing is considered inappropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, there is concern as to the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</div></li><li class="half_rhythm"><div>For more information, see the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</div></li></ul><p>In a family with an established diagnosis of XDP, it is appropriate to consider testing of symptomatic individuals regardless of age.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="xdp.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>TAF1/DYT3</i> disease-associated haplotype has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for XDP are possible.</p><p>Note: Caution should be exercised in interpreting the results of prenatal testing as the <a class="figpopup" href="/books/NBK1489/table/xdp.T.selected_variants_within_the_xdp_c/?report=objectonly" target="object" rid-figpopup="figxdpTselectedvariantswithinthexdpc" rid-ob="figobxdpTselectedvariantswithinthexdpc">c.94C&#x0003e;T</a> (<a class="figpopup" href="/books/NBK1489/table/xdp.T.selected_variants_within_the_xdp_c/?report=objectonly" target="object" rid-figpopup="figxdpTselectedvariantswithinthexdpc" rid-ob="figobxdpTselectedvariantswithinthexdpc">p.Arg32Cys</a>) variant that marks the disease haplotype has not been proven to be the molecular cause of XDP.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="xdp.Resources"><h2 id="_xdp_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>American Parkinson Disease Association (APDA)</b></div><div>135 Parkinson Avenue</div><div>Staten Island NY 10305</div><div><b>Phone:</b> 800-223-2732 (toll-free); 718-981-8001</div><div><b>Fax:</b> 718-981-4399</div><div><b>Email:</b> apda@apdaparkinson.org</div><div><a href="http://www.apdaparkinson.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.apdaparkinson.org</a></div></li><li class="half_rhythm"><div><b>Dystonia Medical Research Foundation</b></div><div>One East Wacker Drive</div><div>Suite 1730</div><div>Chicago IL 60601-1905</div><div><b>Phone:</b> 800-377-3978 (toll-free); 312-755-0198</div><div><b>Fax:</b> 312-803-0138</div><div><b>Email:</b> dystonia@dystonia-foundation.org</div><div><a href="http://www.dystonia-foundation.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.dystonia-foundation.org</a></div></li><li class="half_rhythm"><div><b>Parkinson's Foundation</b></div><div>200 SE 1st Street</div><div>Suite 800</div><div>Miami FL 33131</div><div><b>Phone:</b> 800-4PD-INFO (473-4636)</div><div><b>Email:</b> contact@parkinson.org</div><div><a href="http://www.parkinson.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.parkinson.org</a></div></li></ul></div><div id="xdp.Molecular_Genetics"><h2 id="_xdp_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="xdp.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>X-Linked Dystonia-Parkinsonism Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1489/table/xdp.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xdp.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_xdp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_xdp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_xdp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_xdp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_xdp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_xdp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_xdp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/6872" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>TAF1</i></a></td><td headers="hd_b_xdp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=6872" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xq13<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_xdp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P21675" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Transcription initiation factor TFIID subunit 1</a></td><td headers="hd_b_xdp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/TAF1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TAF1 @ LOVD</a></td><td headers="hd_b_xdp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=TAF1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TAF1</a></td><td headers="hd_b_xdp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=TAF1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TAF1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="xdp.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="xdp.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for X-Linked Dystonia-Parkinsonism Syndrome (<a href="/omim/313650,314250" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1489/table/xdp.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xdp.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/313650" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">313650</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TAF1 RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 250-KD; TAF1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/314250" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">314250</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DYSTONIA 3, TORSION, X-LINKED; DYT3</td></tr></tbody></table></div></div><div id="xdp.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p>Though first described in 1976, it was only in 1990 that <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> dystonia-parkinsonism (XDP) was formally shown through <a class="def" href="/books/n/gene/glossary/def-item/segregation/">segregation</a> and biochemical analyses to be inherited as an X-linked trait [<a class="bk_pop" href="#xdp.REF.kupke.1990b.237">Kupke et al 1990b</a>]. This dispelled previous theories that XDP may be caused by environmental factors (similar to the then-prevailing theory on the cause of Guamanian ALS-parkinsonism) or by metabolic defects. Confirmation of X-linked inheritance of XDP came with the assignment of the disease <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> to Xq21 by linkage analysis [<a class="bk_pop" href="#xdp.REF.kupke.1990a.1438">Kupke et al 1990a</a>].</p><div id="xdp.XDP_Critical_Region"><h4>XDP Critical Region</h4><p>The <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> identified with <i>lubag</i> (DYT3) was proposed to be a multiple transcript system within the XDP <a class="def" href="/books/n/gene/glossary/def-item/critical-region/">critical region</a>. In this complex transcriptional unit, different transcript <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> share some of the 3' <i>TAF1</i> exons as well as additional exons downstream (termed exons d1-d5). These latter exons can also be transcribed independently [<a class="bk_pop" href="#xdp.REF.nolte.2003.10347">Nolte et al 2003</a>, <a class="bk_pop" href="#xdp.REF.herzfeld.2007.787">Herzfeld et al 2007</a>]. The <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> and transcriptional structure of the XDP critical region is being refined; some conflicting results remain to be resolved [<a class="bk_pop" href="#xdp.REF.muller.2007.415">Muller et al 2007</a>, <a class="bk_pop" href="#xdp.REF.tamiya.2007.417">Tamiya et al 2007</a>].</p><p>It is difficult to predict cellular pathways which are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> in XDP cells. Vaine and colleagues assayed expression of defined <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> sets in XDP versus control fibroblasts to identify networks of functionally related transcripts which may be dysregulated in XDP cells [<a class="bk_pop" href="#xdp.REF.vaine.2017.108">Vaine et al 2017</a>]. The analysis derived a 51-gene signature distinguishing XDP versus control fibroblasts which mapped strongly to nuclear factor-kappa B (NF&#x003ba;B), a <a class="def" href="/books/n/gene/glossary/def-item/transcription-factor/">transcription factor</a> pathway also implicated in the pathogenesis of other neurodegenerative diseases, including Parkinson and Huntington disease.</p><p><b>Gene structure.</b>
<i>TAF1</i> (reference sequences <a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=187761327" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004606.3</a>, <a href="/entrez/viewer.fcgi?db=protein&#x00026;id=20357585" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_004597.2</a>) has 38 exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1489/#xdp.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b>
<a class="bk_pop" href="#xdp.REF.nolte.2003.10347">Nolte et al [2003]</a> described five XDP-specific changes (DSC) (DSC1, 2, 3, 10, and 12) as well as a 48-bp <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> in the XDP <a class="def" href="/books/n/gene/glossary/def-item/critical-region/">critical region</a> that mark a <i>TAF1/DYT3</i> disease-associated haplotype. These DSCs as well as the 48-bp deletion were found in all Filipino individuals with XDP, but not in normal Filipino controls with no family history of XDP or in other populations with similar phenotypes. <a class="bk_pop" href="#xdp.REF.nolte.2003.10347">Nolte et al [2003]</a> suggested that it is likely that DSC3 plays a pathogenic role in XDP, although the other XDP-specific sequence changes may also contribute to the disease.</p><p>None of the DSCs was located within a structural or regulatory region of a known <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>. Rather, most changes occurred within repetitive DNA:</p><ul><li class="half_rhythm"><div>DSC1 is located within an Alu repeat, DSC2 within a LINE2 repeat, and DSC10 within a LIMB2 repeat in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 32 of <i>TAF1</i>. DSC12 is located in intron 18 of <i>TAF1</i>, whereas the 48-bp <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> is located in intron 2 of <i>TAF1</i>.</div></li><li class="half_rhythm"><div>Only DSC3 (<a class="figpopup" href="/books/NBK1489/table/xdp.T.selected_variants_within_the_xdp_c/?report=objectonly" target="object" rid-figpopup="figxdpTselectedvariantswithinthexdpc" rid-ob="figobxdpTselectedvariantswithinthexdpc">c.94C&#x0003e;T</a> (<a class="figpopup" href="/books/NBK1489/table/xdp.T.selected_variants_within_the_xdp_c/?report=objectonly" target="object" rid-figpopup="figxdpTselectedvariantswithinthexdpc" rid-ob="figobxdpTselectedvariantswithinthexdpc">p.Arg32Cys</a>) in <i>DYT3</i>) is embedded in a predicted exonic DNA sequence, located in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> "d4." The DSC3 variant was not detected in unaffected Filipino or other non-Filipino populations and is the only molecular alteration detected in a mature transcript within the XDP core haplotype. <a class="bk_pop" href="#xdp.REF.nolte.2003.10347">Nolte et al [2003]</a> concluded that it is likely that DSC3 plays a pathogenic role in XDP, although other XDP-specific sequence changes may also contribute to the disease (e.g., by influencing <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> of transcripts). To date, XDP is known only in persons of Filipino descent, suggesting genetic homogeneity.</div></li></ul><p>Using <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> sequencing analysis followed by expression analysis of XDP in brain tissues, <a class="bk_pop" href="#xdp.REF.makino.2007.393">Makino et al [2007]</a> reported a disease-specific <i>s</i>hort interspersed nuclear element, <i>v</i>ariable number of tandem repeats, and <i>A</i>lu composite (SVA) retrotransposon <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 32 of <i>TAF1</i>, with significantly reduced expression of <i>TAF1</i> and <i>DDR2</i> (encoding the dopamine receptor D<sub>2</sub>) in the caudate nucleus of individuals with XDP [<a class="bk_pop" href="#xdp.REF.makino.2007.393">Makino et al 2007</a>].</p><div id="xdp.T.selected_variants_within_the_xdp_c" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected Variants within the XDP Critical Region</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1489/table/xdp.T.selected_variants_within_the_xdp_c/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xdp.T.selected_variants_within_the_xdp_c_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_xdp.T.selected_variants_within_the_xdp_c_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene/Locus</th><th id="hd_h_xdp.T.selected_variants_within_the_xdp_c_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_xdp.T.selected_variants_within_the_xdp_c_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_xdp.T.selected_variants_within_the_xdp_c_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_xdp.T.selected_variants_within_the_xdp_c_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_xdp.T.selected_variants_within_the_xdp_c_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TAF1/DYT3</i></td><td headers="hd_h_xdp.T.selected_variants_within_the_xdp_c_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pathogenic / Marker</td><td headers="hd_h_xdp.T.selected_variants_within_the_xdp_c_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.94C&#x0003e;T</td><td headers="hd_h_xdp.T.selected_variants_within_the_xdp_c_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg32Cys<br />(DSC3)</td><td headers="hd_h_xdp.T.selected_variants_within_the_xdp_c_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=34481726" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AJ549245<wbr style="display:inline-block"></wbr>​.1</a>&#x000a0;<sup>2</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="xdp.TF.2.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="xdp.TF.2.2"><p class="no_margin">The variant c.94C&#x0003e;T (p.Arg32Cys) is named on the reference sequence for <i>DYT3.</i></p></div></dd></dl></div></div></div><p><a class="bk_pop" href="#xdp.REF.bragg.2017.e11020">Bragg et al [2017]</a> have further analyzed the sequence of the SVA in <i>TAF1</i> and detected polymorphic variation in the length of a hexanucleotide repeat <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, (CCCTCT)n, which varies from 35 to 52 repeats. The length of the repeat correlates inversely with age at disease onset [<a class="bk_pop" href="#xdp.REF.bragg.2017.e11020">Bragg et al 2017</a>].</p><p><b>Molecular mechanisms in symptomatic women with XDP.</b> The majority of symptomatic women with <i>lubag</i> are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>TAF1/DYT3</i> disease-associated haplotype, thus suggesting extremely skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>. Rarely, females may be symptomatic due to homozygosity for the <i>TAF1/DYT3</i> disease-associated haplotype [<a class="bk_pop" href="#xdp.REF.evidente.2004b.1956">Evidente et al 2004b</a>, <a class="bk_pop" href="#xdp.REF.domingo.2014.1177">Domingo et al 2014</a>].</p><p>The loss of one X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in a subset of cells or X-chromosome <a class="def" href="/books/n/gene/glossary/def-item/monosomy/">monosomy</a> (45,X / 46,XX) has also been noted in a female with XDP and a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> similar to Turner syndrome [<a class="bk_pop" href="#xdp.REF.westenberger.2013.675">Westenberger et al 2013</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Unknown</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Whether an abnormal protein product results from the DSC3 (c.94C&#x0003e;T;p.Arg32Cys) variant in <i>DYT3</i> is unknown. <a class="bk_pop" href="#xdp.REF.nolte.2003.10347">Nolte et al [2003]</a> hypothesized that the <i>DYT3</i>-specific sequence changes could contribute to the disease by influencing <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> of transcripts. However, <a class="bk_pop" href="#xdp.REF.makino.2007.393">Makino et al [2007]</a> suggested that the SVA retrotransposon <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> into <i>TAF1</i> may cause XDP by altering expression of <i>TAF1</i> <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> (including the neuron-specific TA14-391), possibly through DNA <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> alterations. The decreased expression of the TA14-391 isoform (and possibly other <i>TAF1</i> isoforms) in XDP brains may result in transcriptional dysregulation of many neuronal genes, including <i>DRD2</i>.</p><p>Although the individual or combined roles of DSC3, the other DSCs, and the SVA retrotransposon in pathogenesis of XDP remain to be determined, more recent work by <a class="bk_pop" href="#xdp.REF.herzfeld.2013.941">Herzfeld et al [2013]</a> suggests that the DSC3 in <i>TAF1/DYT3</i> interferes with dopamine processing and function, as well as calcium metabolism leading to impaired vesicular neurotransmitter release.</p><p>Ito and colleagues generated XDP and control fibroblasts and induced pluripotent stem cells (iPSCs) in order to further probe cellular defects associated with XDP [<a class="bk_pop" href="#xdp.REF.ito.2016.451">Ito et al 2016</a>]. They compared expression of TAF1 and MTS transcripts in XDP versus control fibroblasts and iPSC-derived neural stem cells (NSCs). Compared with control cells, XDP fibroblasts exhibited decreased expression of TAF1 transcript fragments derived from exons 32-36, a region spanning the SVA <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> site. N-TAF1, which incorporates an alternative <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> (exon 34'), was not expressed in fibroblasts, but was detectable in iPSC-differentiated NSCs at levels that were three times lower in XDP cells than in controls. Thus, not only do these new data support the previous findings that N-TAF1 expression is impaired in XDP, but additionally indicate that this aberrant transcription could occur in neural cells at relatively early stages of development that precede neurodegeneration.</p></div></div></div><div id="xdp.References"><h2 id="_xdp_References_">References</h2><div id="xdp.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.aguilar.2011.57">Aguilar JA, Vesagas TS, Jamora RD, Teleg RA, Ledesma L, Rosales RL, Fernandez HH, Lee HV. The promise of deep brain stimulation in X-linked dystonia parkinsonism. <span><span class="ref-journal">Int J Neurosci. </span>2011;<span class="ref-vol">121</span> Suppl 1:57–63.</span> [<a href="/pubmed/21244299" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21244299</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.bragg.2017.e11020">Bragg DC, Mangkalaphiban K, Vaine CA, Kulkarni NJ, Shin D, Yadav R, Dhakal J, Ton ML, Cheng A, Russo CT, Ang M, Acu&#x000f1;a P, Go C, Franceour TN, Multhaupt-Buell T, Ito N, M&#x000fc;ller U, Hendriks WT, Breakefield XO, Sharma N, Ozelius LJ. Disease onset in X-linked dystonia-parkinsonism correlates with expansion of a hexameric repeat within an SVA retrotransposon in TAF1. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2017;<span class="ref-vol">114</span>:E11020–28.</span> [<a href="/pmc/articles/PMC5754783/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5754783</span></a>] [<a href="/pubmed/29229810" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29229810</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.br_ggemann.2017.680">Br&#x000fc;ggemann N, Rosales RL, Waugh JL, Blood AJ, Domingo A, Heldmann M, Jamora RD, M&#x000fc;nchau A, M&#x000fc;nte TF, Lee LV, Buchmann I, Klein C. Striatal dysfunction in X-linked dystonia-parkinsonism is associated with disease progression. <span><span class="ref-journal">Eur J Neurol. </span>2017;<span class="ref-vol">24</span>:680–6.</span> [<a href="/pubmed/28236370" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28236370</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.br_ggemann.2016.91">Br&#x000fc;ggemann N, Heldmann M, Klein C, Domingo A, Rasche R, Tronnier V, Rosales RL, Jamora RFG, Lee LV, M&#x000fc;nte TF. Neuroanatomical changes extend beyond striatal atrophy in X-linked dystonia parkinsonism. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2016;<span class="ref-vol">31</span>:91–7.</span> [<a href="/pubmed/27481033" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27481033</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.daniele.1997.1222">Daniele A, Albanese A, Gainotti G, Gregori B, Bartolomeo P. Zolpidem in Parkinson's disease. <span><span class="ref-journal">Lancet. </span>1997;<span class="ref-vol">349</span>:1222–3.</span> [<a href="/pubmed/9130951" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9130951</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.daniele.1999.543">Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. <span><span class="ref-journal">N Engl J Med. </span>1999;<span class="ref-vol">341</span>:543–4.</span> [<a href="/pubmed/10447452" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10447452</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.domingo.2011.s264">Domingo AR, Ledesma LKD, Pasco PM, Jamora RDG, Lee LV. Neuropsychological profile of X-linked dystonia parkinsonism (XDP, DYT3). <span><span class="ref-journal">Mov Disord. </span>2011;<span class="ref-vol">26</span> Suppl 2:S264.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.domingo.2014.1177">Domingo A, Lee LV, Bruggemann N, Freimann K, Kaiser FJ, Jamora RD, Rosales RL, Klein C, Westenberger A. Woman with x-linked recessive dystonia-parkinsonism: clue to the epidemiology of parkinsonism in Filipino women? <span><span class="ref-journal">JAMA Neurol. </span>2014;<span class="ref-vol">71</span>:1177–80.</span> [<a href="/pubmed/25004170" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25004170</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.eidelberg.1993.185">Eidelberg D, Takikawa S, Wilhelmsen K, Dhawan V, Chaly T, Robeson W, Dahl R, Margouleff D, Greene P, Hunt A, et al.  Positron emission tomographic findings in Filipino X-linked dystonia-parkinsonism. <span><span class="ref-journal">Ann Neurol. </span>1993;<span class="ref-vol">34</span>:185–91.</span> [<a href="/pubmed/8338342" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8338342</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.evidente.2002.662">Evidente VG. Zolpidem improves dystonia in "Lubag" or X-linked dystonia-parkinsonism syndrome. <span><span class="ref-journal">Neurology. </span>2002;<span class="ref-vol">58</span>:662–3.</span> [<a href="/pubmed/11865155" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11865155</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.evidente.2002a.1271">Evidente VG, Advincula J, Esteban R, Pasco P, Alfon JA, Natividad FF, Cuanang J, Luis AS, Gwinn-Hardy K, Hardy J, Hernandez D, Singleton A. Phenomenology of "Lubag" or X-linked dystonia-parkinsonism. <span><span class="ref-journal">Mov Disord. </span>2002a;<span class="ref-vol">17</span>:1271–7.</span> [<a href="/pubmed/12465067" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12465067</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.evidente.2002b.294">Evidente VG, Dickson D, Singleton A, Natividad F, Hardy J, Hernandez D. Novel neuropathological findings in Lubag or x-linked dystonia-parkinsonism. <span><span class="ref-journal">Mov Disord. </span>2002b;<span class="ref-vol">17</span> Suppl 1:294.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.evidente.2004a.407">Evidente VG, Esteban RP, Hernandez JL, Natividad FF, Advincula J, Gwinn-Hardy K, Hardy J, Singleton A, Singleton A. Smell testing is abnormal in 'lubag' or X-linked dystonia-parkinsonism: a pilot study. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2004a;<span class="ref-vol">10</span>:407–10.</span> [<a href="/pubmed/15465396" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15465396</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.evidente.2007.1790">Evidente VG, Lyons MK, Wheeler M, Hillman R, Helepolelei L, Beynen F, Nolte D, Muller U, Starr PA. First case of X-linked dystonia-parkinsonism ('Lubag') to demonstrate a response to bilateral pallidal stimulation. <span><span class="ref-journal">Mov Disord. </span>2007;<span class="ref-vol">22</span>:1790–3.</span> [<a href="/pubmed/17579361" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17579361</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.evidente.2004b.1956">Evidente VG, Nolte D, Niemann S, Advincula J, Mayo MC, Natividad FF, Muller U. Phenotypic and molecular analyses of X-linked dystonia-parkinsonism ('lubag') in women. <span><span class="ref-journal">Arch Neurol. </span>2004b;<span class="ref-vol">61</span>:1956–9.</span> [<a href="/pubmed/15596620" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15596620</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.evidente.2002c.200">Evidente VGH, Gwinn-Hardy K, Hardy J, Hernandez D, Singleton A. X-linked dystonia ("Lubag") presenting predominantly with parkinsonism: A more benign phenotype? <span><span class="ref-journal">Mov Disord. </span>2002c;<span class="ref-vol">17</span>:200–2.</span> [<a href="/pubmed/11835466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11835466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.evidente.2002d.626">Evidente VGH, Santiago J, Fugoso L, Natividad FF. Fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) brain imaging findings in symptomatic and asymptomatic carriers of X-linked dystonia-parkinsonism ("Lubag"). <span><span class="ref-journal">Mov Disord. </span>2002d;<span class="ref-vol">21</span> Suppl 15:626.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.gillian.2013.299">Gillian LS. Pathological gambling in X-linked dystonia Parkinsonism. <span><span class="ref-journal">J Addict Med. </span>2013;<span class="ref-vol">7</span>:299–301.</span> [<a href="/pubmed/23629417" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23629417</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.goto.2005.7">Goto S, Lee LV, Munoz EL, Tooyama I, Tamiya G, Makino S, Ando S, Dantes MB, Yamada K, Matsumoto S, Shimazu H, Kuratsu J, Hirano A, Kaji R. Functional anatomy of the basal ganglia in x-linked recessive dystonia-parkinsonism. <span><span class="ref-journal">Ann Neurol. </span>2005;<span class="ref-vol">58</span>:7–17.</span> [<a href="/pubmed/15912496" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15912496</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.goto.2013.1555">Goto S, Kawarai T, Morigaki R, Okita S, Koizumi H, Nagahiro S, Munoz EL, Lee LV, Kaji R. Defects in the striatal neuropeptide Y system in X-linked dystonia-parkinsonism. <span><span class="ref-journal">Brain. </span>2013;<span class="ref-vol">136</span>:1555–67.</span> [<a href="/pubmed/23599389" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23599389</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.herzfeld.2007.787">Herzfeld T, Nolte D, M&#x000fc;ller U. Structural and functional analysis of the human TAF1/DYT3 multiple transcript system. <span><span class="ref-journal">Mamm Genome. </span>2007;<span class="ref-vol">18</span>:787–95.</span> [<a href="/pubmed/17952504" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17952504</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.herzfeld.2013.941">Herzfeld T, Nolte D, Grznarova M, Hofmann A, Schultze J, Muller U. X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific sequence change DSC3 TAF1/DYT3 affects genes in vesicular transport and dopamine metabolism. <span><span class="ref-journal">Hum Mol Genet. </span>2013;<span class="ref-vol">22</span>:941–51.</span> [<a href="/pubmed/23184149" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23184149</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.ito.2016.451">Ito N, Hendriks WT, Dhakal J, Vaine CA, Liu C, Shin D, Shin K, Wakabayashi-Ito N, Dy M, Multhaupt-Buell T, Sharma N, Breakefield XO, Bragg DC. Decreased N-TAF1 expression in X-linked dystonia-parkinsonism patient-specific neural stem cells. <span><span class="ref-journal">Dis Model Mech. </span>2016;<span class="ref-vol">9</span>:451–62.</span> [<a href="/pmc/articles/PMC4852502/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4852502</span></a>] [<a href="/pubmed/26769797" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26769797</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.kupke.1990a.1438">Kupke KG, Lee LV, Muller U. Assignment of the X-linked recessive torsion dystonia gene to Xq21 by linkage analysis. <span><span class="ref-journal">Neurology. </span>1990a;<span class="ref-vol">40</span>:1438–42.</span> [<a href="/pubmed/1975433" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1975433</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.kupke.1990b.237">Kupke KG, Lee LV, Viterbo GH, Arancillo J, Donlon T, Muller U. X-linked recessive torsion dystonia in the Philippines. <span><span class="ref-journal">Am J Med Genet. </span>1990b;<span class="ref-vol">36</span>:237–42.</span> [<a href="/pubmed/2368812" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2368812</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.lee.2002.29">Lee LV, Maranon E, Demaisip C, Peralta O, Borres-Icasiano R, Arancillo J, Rivera C, Munoz E, Tan K, Reyes MT. The natural history of sex-linked recessive dystonia parkinsonism of Panay, Philippines (XDP). <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2002;<span class="ref-vol">9</span>:29–38.</span> [<a href="/pubmed/12217620" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12217620</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.lee.1976.137">Lee LV, Pascasio FM, Fuentes FD, Viterbo GH. Torsion dystonia in Panay, Philippines. <span><span class="ref-journal">Adv Neurol. </span>1976;<span class="ref-vol">14</span>:137–51.</span> [<a href="/pubmed/941767" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 941767</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.lee.2011.3">Lee LV, Rivera C, Teleg RA, Dantes MB, Pasco PMD, Jamora RDG, Arancill J, Villareal-Jordan RF, Rosales RL, Demaisip C, Maranon E, Peralta O, Borres R, Tolentino C, Monding MR, Sarcia S. The unique phenomenology of sex-linked dystonia parkinsonism (XDP, DT3, "Lubag"). <span><span class="ref-journal">Int J Neurosci. </span>2011;<span class="ref-vol">121</span>:3–11.</span> [<a href="/pubmed/21047175" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21047175</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.makino.2007.393">Makino S, Kaji R, Ando S, Tomizawa M, Yasuno K, Goto S, Matsumoto S, Tabuena MD, Maranon E, Dantes M, Lee LV, Ogasawara K, Tooyama I, Akatsu H, Nishimura M, Tamiya G. Reduced neuron-specific expression of the TAF1 gene is associated with x-linked dystonia-parkinsonism. <span><span class="ref-journal">Am J Hum Genet. </span>2007;<span class="ref-vol">80</span>:393–406.</span> [<a href="/pmc/articles/PMC1821114/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1821114</span></a>] [<a href="/pubmed/17273961" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17273961</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.martineztorres.2009.1710">Martinez-Torres I, Limousin P, Tisch S, Page R, Pinto A, Foltynie T, Bhatia KP, Hariz MI, Zrinzo L. Early and marked benefit with GPi DBS for Lubag syndrome presenting with rapidly progressive life-threatening dystonia. <span><span class="ref-journal">Mov Disord. </span>2009;<span class="ref-vol">24</span>:1710–2.</span> [<a href="/pubmed/19514062" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19514062</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.morigaki.2013.844">Morigaki R, Nakataki M, Kawarai T, Lee LV, Teleg RA, Tabuena MD, Mure H, Sako W, Pasco PM, Nagahiro S, Iga J, Ohmori T, Goto S, Kaji R. Depression in X-linked dystonia-parkinsonism: a case-control study. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2013;<span class="ref-vol">19</span>:844–6.</span> [<a href="/pubmed/23706616" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23706616</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.muller.2007.415">Muller U, Herzfeld T, Nolte D. The TAF1/DYT3 multiple transcript system in X-linked dystonia-parkinsonism. <span><span class="ref-journal">Am J Hum Genet. </span>2007;<span class="ref-vol">81</span>:415–7.</span> [<a href="/pmc/articles/PMC1950800/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1950800</span></a>] [<a href="/pubmed/17668393" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17668393</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.nolte.2003.10347">Nolte D, Niemann S, Muller U. Specific sequence changes in multiple transcript system DYT3 are associated with X-linked dystonia parkinsonism. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2003;<span class="ref-vol">100</span>:10347–52.</span> [<a href="/pmc/articles/PMC193564/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC193564</span></a>] [<a href="/pubmed/12928496" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12928496</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.oyama.2010.329">Oyama G, Fernandez HH, Foote KD, Zeilman P, Hwynn N, Jacobson CE IV, Malaty IA, Rodriguez RL, Okun MS. Differential response of dystonia and parkinsonism following globus pallidus internus deep brain stimulation in X-linked dystonia-parkinsonism (Lubag). <span><span class="ref-journal">Stereotact Funct Neurosurg. </span>2010;<span class="ref-vol">88</span>:329–33.</span> [<a href="/pmc/articles/PMC2969112/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2969112</span></a>] [<a href="/pubmed/20714213" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20714213</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.pasco.2011.12">Pasco PM, Ison CV, Mu&#x000f1;oz EL, Magpusao NS, Cheng AE, Tan KT, Lo RW, Teleg RA, Dantes MB, Borres R, Maranon E, Demaisip C, Reyes MV, Lee LV. Understanding XDP through imaging, pathology, and genetics. <span><span class="ref-journal">Int J Neurosci. </span>2011;<span class="ref-vol">121</span> Suppl 1:12–7.</span> [<a href="/pubmed/21034368" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21034368</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.patel.2014.241.e1">Patel AJ, Sarwar AI, Jankovic J, Viswanathan A. Bilateral pallidal deep brain stimulation for X-linked dystonia-parkinsonism. <span><span class="ref-journal">World Neurosurg. </span>2014;<span class="ref-vol">82</span>:241.e1–4.</span> [<a href="/pubmed/24076056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24076056</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.piano.2013.1069">Piano AN, Tan LC. Impulse control disorder in a patient with X-linked dystonia-parkinsonism after bilateral pallidal deep brain stimulation. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2013;<span class="ref-vol">19</span>:1069–70.</span> [<a href="/pubmed/23920134" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23920134</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.rosales.2011.44">Rosales RL, Ng AR, Santos MM, Fernandez HH. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport&#x000ae;) injections for oromandibular, lingual, and truncal-axial dystonias. <span><span class="ref-journal">Int J Neurosci. </span>2011;<span class="ref-vol">121</span> Suppl 1:44–56.</span> [<a href="/pubmed/21348790" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21348790</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.tackenberg.2007.900">Tackenberg B, Metz A, Unger M, Schimke N, Passow S. Nigrostriatal dysfunction in X-linked dystonia-parkinsonism. <span><span class="ref-journal">Mov Disord. </span>2007;<span class="ref-vol">22</span>:900–2.</span> [<a href="/pubmed/17377924" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17377924</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.tamiya.2007.417">Tamiya G, Makino S, Kaji R. TAF1 as the most plausible disease gene for XDP/DYT3. <span><span class="ref-journal">Am J Hum Genet. </span>2007;<span class="ref-vol">81</span>:417–8.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.vaine.2017.108">Vaine CA, Shin D, Liu C, Hendriks WT, Dhakal J, Shin K, Sharma N, Bragg DC. X-linked Dystonia-Parkinsonism patient cells exhibit altered signaling via nuclear factor-kappa B. <span><span class="ref-journal">Neurobiol Dis. </span>2017;<span class="ref-vol">100</span>:108–18.</span> [<a href="/pmc/articles/PMC5316362/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5316362</span></a>] [<a href="/pubmed/28017799" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28017799</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.wadia.2010.1012">Wadia PM, Lim SY, Lozano AM, Adams JR, Poon YY, Torres Diaz CV, Moro E. Bilateral pallidal stimulation for x-linked dystonia parkinsonism. <span><span class="ref-journal">Arch Neurol. </span>2010;<span class="ref-vol">67</span>:1012–5.</span> [<a href="/pubmed/20697054" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20697054</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.walter.2017.43">Walter U, Rosales R, Rocco A, Westenberger A, Domingo A, Go CL, Br&#x000fc;ggemann N, Klein C, Lee LV, Dressler D. Sonographic alteration of substantia nigra isrelated to parkinsonism-predominant course of X-linked dystonia-parkinsonism. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2017;<span class="ref-vol">37</span>:43–9.</span> [<a href="/pubmed/28094105" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28094105</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.waters.1993.1555">Waters CH, Takahashi H, Wilhelmsen KC, Shubin R, Snow BJ, Nygaard TG, Moskowitz CB, Fahn S, Calne DB. Phenotypic expression of X-linked dystonia-parkinsonism (lubag) in two women. <span><span class="ref-journal">Neurology. </span>1993;<span class="ref-vol">43</span>:1555–8.</span> [<a href="/pubmed/8351010" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8351010</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xdp.REF.westenberger.2013.675">Westenberger A, Rosales RL, Heinitz S, Freimann K, Lee LV, Jamora RD, Ng AR, Domingo A, Lohmann K, Walter U, Golnit U, Rolfs A, Nagel I, Gillessen-Kaesbach G, Siebert R, Dressler D, Klein C. X-linked dystonia-parkinsonism manifesting in a female patient due to atypical Turner syndrome. <span><span class="ref-journal">Mov Disord. </span>2013;<span class="ref-vol">28</span>:675–8.</span> [<a href="/pubmed/23389859" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23389859</span></a>]</div></li></ul></div></div><div id="xdp.Chapter_Notes"><h2 id="_xdp_Chapter_Notes_">Chapter Notes</h2><div id="xdp.Acknowledgments"><h3>Acknowledgments</h3><p>Dr Evidente has received research support from the Udall PD Research Center of Excellence Grant #P50 NS40256, Mayo Clinic Foundation, and St Luke's Medical Center Research &#x00026; Biotechnology Division (Philippines).</p></div><div id="xdp.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>15 February 2018 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>23 April 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>18 October 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>22 June 2010 (cd) Revision: prenatal testing available</div></li><li class="half_rhythm"><div>27 April 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>6 January 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>13 December 2005 (me) Review posted live</div></li><li class="half_rhythm"><div>8 March 2005 (vge) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1489</span><span class="label">PMID: <a href="/pubmed/20301662" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301662</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/csnb/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/xlhi/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1489&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1489/?report=reader">PubReader</a></li><li><a href="/books/NBK1489/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1489" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1489" style="display:none" title="Cite this Page"><div class="bk_tt">Evidente VGH. X-Linked Dystonia-Parkinsonism. 2005 Dec 13 [Updated 2018 Feb 15]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1489/pdf/Bookshelf_NBK1489.pdf">PDF version of this page</a> (222K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#xdp.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#xdp.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#xdp.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#xdp.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#xdp.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#xdp.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#xdp.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#xdp.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#xdp.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#xdp.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#xdp.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6872[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TAF1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1489+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1491864" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1491864" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1491864" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1491864" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24868378" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-linked dystonia parkinsonism: clinical phenotype, genetics and therapeutics.</a><span class="source">[J Mov Disord. 2010]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-linked dystonia parkinsonism: clinical phenotype, genetics and therapeutics.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Rosales RL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Mov Disord. 2010 Oct; 3(2):32-8. Epub 2010 Oct 30.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15596620" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Phenotypic and molecular analyses of X-linked dystonia-parkinsonism ("lubag") in women.</a><span class="source">[Arch Neurol. 2004]</span><div class="brieflinkpop offscreen_noflow">Phenotypic and molecular analyses of X-linked dystonia-parkinsonism ("lubag") in women.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Evidente VG, Nolte D, Niemann S, Advincula J, Mayo MC, Natividad FF, Müller U. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Arch Neurol. 2004 Dec; 61(12):1956-9. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301294" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301718" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">PLA2G6</i>-Associated Neurodegeneration</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">PLA2G6</i>-Associated Neurodegeneration<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gregory A, Kurian MA, Maher ER, Hogarth P, Hayflick SJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28749637" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">SLC6A3</i>-Related Dopamine Transporter Deficiency Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">SLC6A3</i>-Related Dopamine Transporter Deficiency Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kurian MA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301662" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301662" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04162839a66ee2ba162d2d">X-Linked Dystonia-Parkinsonism - GeneReviews®</a><div class="ralinkpop offscreen_noflow">X-Linked Dystonia-Parkinsonism - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:08:40-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8A08F6E04125D10000000001A600AB&amp;ncbi_session=CE8A08F6E0416271_0422SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1489%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1489&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1489/&amp;ncbi_pagename=X-Linked Dystonia-Parkinsonism - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A08F6E0416271_0422SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>